Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azvudine in symptomatic adults with COVID-19 at risk of severe illness
NCT05689034Phase 3Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of azvudine in coronavirus disease 2019 (COVID-19), sponsored by Peking Union Medical College Hospital. Primary endpoint: Proportion of COVID-19-related critical illness or all-cause death at 28 days. Started Apr 2023; status: recruiting.
02
Drugs
azvudine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05689034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05689034.